BioSpace

BMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma win

The centerpiece of Bristol Myers Squibb’s 2024 RayzeBio buy has read out, hitting the primary endpoint in a late-stage tumor trial.

By BioSpace

1 min read
BMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma win
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights